Comparative economic analysis of aromatase inhibitors and tamoxifen in the treatment of hormone-dependent breast cancer

Expert Opinion on Pharmacotherapy

Volumn 8, Issue 11, 2007, Pages 1675-1691

  Miller, Lesley Ann N ^a   Roy, Anuja ^b   Mody, Reema ^c   Higa, Gerald M ^b  

^a UNIVERSITY OF TEXAS   (United States)

^b WEST VIRGINIA UNIVERSITY   (United States)

^c TAP PHARMACEUTICAL PRODUCTS INC   (United States)

Author keywords

Anastrozole; Aromatase inhibitor; Cost; Cost effectiveness; Economic evaluation; Exemestane; Letrozole; Tamoxifen; Utility

Indexed keywords

ANASTROZOLE; AROMATASE INHIBITOR; ESTROGEN; ESTROGEN RECEPTOR; EXEMESTANE; HORMONE; LETROZOLE; MEGESTROL; TAMOXIFEN; TRASTUZUMAB;

BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER HORMONE THERAPY; CANCER RELAPSE; CANCER SURVIVAL; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; COMPARATIVE STUDY; COST EFFECTIVENESS ANALYSIS; DATA SYNTHESIS; DRUG COST; DRUG EFFICACY; DRUG TOLERABILITY; ECONOMIC EVALUATION; HUMAN; MONOTHERAPY; POSTMENOPAUSE; PRACTICE GUIDELINE; PRIMARY HEALTH CARE; QUALITY OF LIFE; REVIEW; UNSPECIFIED SIDE EFFECT;

ANIMALS; AROMATASE INHIBITORS; BREAST NEOPLASMS; FEMALE; HUMANS; NEOPLASMS, HORMONE-DEPENDENT; SELECTIVE ESTROGEN RECEPTOR MODULATORS; TAMOXIFEN;

EID: 34548080977     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.8.11.1675     Document Type: Review

References (45)

1. HENDERSON IC, CANELLOS GP: Cancer of the breast The past decade. N. Engl. J. Med. (1980) 302:17-30.
2. JORDAN C: Historical perspective on hormonal therapy of advanced breast cancer. Clin. Ther. (2002) 24(Suppl. A).A3-A16.
3. HIGA GM: Aromatase inhibitors for breast cancer: pharmacoeconomic considerations. Expert Opin. Pharmacother. (2001) 2(6):987-995.
4. MOURIDSEN H, GERSHANOVICH M, SUN Y et al.: Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women from the International Letrozole Breast Cancer Group. J. Clin. Oncol. (2003) 21:2101-2109.
5. PARIDAENS R, THERASSE P, DIRIX L et al.: Fire line hormonal treatment for metastatic breast cancer with exemestane or tamoxifen in postmenopausal patients: a randomized Phase III trial of the EORTC Breast Group. Proc. Am. Soc. Clin. Oncol. (2004) 23:(Abstract 515).
6. ATAC TRIALISTS' GROUP: Results of the ATAC (Arimidex, Tamoxifen alone or in combination) trial after completion of 5 years' of adjuvant treatment for breast cancer. Lancet (2005) 365:60-62.
7. GOSS PE, INGLE JN, MARTINO S et al.: A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N. Engl. J. Med. (2003) 349:1793-1802.
8. COOMBES RC, HALL E, GIBSON LJ et al.: A randomized trial of exemestane after two or three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N. Engl. J. Med. (2004) 350:1081-1092.
9. BIG I-98 COLLABORATIVE GROUP: A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N. Engl. J. Med. (2005) 353:2747-2757.
10. GOLDHIRSCH A, GLICK JH, GELBER RD et al.: Meeting highlights: international expert consensus on the primary therapy of early breast cancer. Ann. Oncol. (2005) 16:1569-1583.
11. ALBAIN K, BARLOW W, O'MALLEY F et al.: Concurrent (CAFT) versus sequential (CAF-T) chemohormonal therapy (cyclophosphamide, doxorubicin, 5-fluorouracil, tamoxifen) versus T alone for postmenopausal, node-positive estrogen (ER) and/or progesterone (PgR) receptor-positive breast cancer, mature outcomes and new biologic correlates on Phase III intergroup trial 0100 (SWOG-8814). Breast Cancer Res. Treat. (2004) 88(Suppl. 1) (Abstract 37).
12. BULAN SE, SIMPSON ER: Regulation of aromatase expression in human tissues. Breast Cancer Res. Treat. (1994) 30:19-29.
13. WANDER HE, BLOSSEY HC, NAGEL GA: Aminoglutethimide in the treatment of premenopausal patients with metastatic breast cancer. Eur. J. Clin. Oncol. (1986) 22:1371-1374.
14. BINES J, OLESKE DM, COBLEIGH MA: Ovarian function in premenopausal women treated with adjuvant chemotherapy for breast cancer. J. Clin. Oncol. (1996) 14:1718-1729.
15. SMITH IE, DOWSETT M, YAP Y-S et al.: Adjuvant aromatase inhibitors for early breast cancer after chemotherapy-induced amenorrhaea: caution and suggested guidelines. J. Clin. Oncol. (2006) 16:2444-2447.
16. STEIN RC, DOWSETT M, HEDLEY A, GAZET JC, FORD HT, COOMBES RC: The clinical and endocrine effects of 4-hydroxyandrostenedione alone and in combination with goserelin in premenopausal women with advanced breast cancer. Br. J. Cancer (1990) 62:679-683.
17. CELIO L, MARTINETYI A, FERRARI L: Premenopausal breast cancer patients treated with a gonadrotropin-releasing hormone analog alone or in combination with an aromatase inhibitor: a comparative endocrine study. Anticancer Res. (1999) 19(3B):2261-2268.
18. FORWARD DP, CHEUNG KL, JACKSON L, ROBERTSON JFR: Clinical and endocrine data for goserelin plus anastrozole as second-line endocrine therapy for premenopausal advanced breast cancer. Br. J. Cancer (2004) 90:590-594.
19. HILLNER BE: Benefit and projected cost-effectiveness of anastrozole versus tamoxifen as initial adjuvant therapy for patients with early-stage estrogen receptor-positive breast cancer. Cancer (2004) 101:1311-1322.
20. ROCCHI A, VERMA S: Anastrozole is cost-effective vs tamoxifen as initial adjuvant therapy in early breast cancer: Canadian perspectives on the ATAC completed-treatment analysis. Support. Care Cancer (2006) 14:917-927.
21. LUNDKVIST J, WILKING N, HOLMBERG S, JONSSON L: Cost-effectiveness of exemestane versus tamoxifen as adjuvant therapy for early-stage breast cancer after 2-3 years treatment with tamoxifen in Sweden. Breast Cancer Res. Treat. (2007) 102(3):289-299.
22. LONNING PE: Comparing cost/utility of giving an aromatase inhibitor as monotherapy for 5 years versus sequential administration following 2-3 or 5 years of tamoxifen as adjuvant treatment for postmenopausal breast cancer. Ann. Oncol. (2006) 17:217-225.
23. GIL JM, RUBIO-TERRES C, DEL CAST1LLO A, GONZALEZ P: Pharmacoeconomic analysis of adjuvant therapy with exemestane, anastrozole, letrozole or tamoxifen in postmenopausal women with operable and estrogen receptor-positive breast cancer. Clin. Transl. Oncol. (2006) 8:339-348.
24. SKEDGEL C, RAYSON D, DEWAR R, YOUNIS T: Cost-utility of adjuvant hormone therapies with aromatase inhibitors in post-menopausal women with breast cancer; upfront anastrozole, sequential tamoxifen-exemestane and extended tamoxifen-letrozole. Breast (2007) 16(3):252-261.
25. KARNON J, DELEA T, JOHNSTON SRD et al.: Cost effectiveness of extended adjuvant letrozole in postmenopausal women after adjuvant tamoxifen therapy: the UK perspective. Pharmacoeconomics (2006) 24:237-250.
26. DELEA TE, KARNON J, SMITH RE et al.: Cost-effectiveness of extended adjuvant letrozole therapy after 5 years of adjuvant tamoxifen therapy in postmenopausal women with early-stage breast cancer. Am. J. Manag. Care (2006) 12:374-386.
27. OUAGARI KE, KARNON J, DELEA T et al.: Cost-effectiveness of letrozole in the extended adjuvant treatment of women with early breast cancer. Breast Cancer Res. Treat. (2007) 101:37-49.
28. SIMONS WR, JONES D, BUZDAR A: Cost-effectiveness of anastrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer. Clin. Ther. (2003) 25:2972-2987.
29. KARNON J, JOHNSTON SRD, JONES T, GLENDENNING A: A trial-based cost-effectiveness analysis of letrozole followed by tamoxifen versus tamoxifen followed by letrozole for postmenopausal advanced breast cancer. Ann. Oncol. (2003) 14:1629-1633.
30. KARNON J, JONES T: A stochastic economic evaluation of letrozole versus tamoxifen as a first-line hormonal therapy: for advanced breast cancer in postmenopausal patients. Pharmacoeconomics (2003) 21:513-525.
31. DRANITSARIS G, VERMA S, TRUDEAU M: Cost utility analysis of first-line hormonal therapy in advanced breast cancer: comparison of two aromatase inhibitors to tamoxifen. Am. J. Clin. Oncol. (2003) 26:289-296.
32. MARCHETTI M, CARUGGI M, COLOMBO G: Cost utility and budget impact of third-generation aromatase inhibitors for advanced breast cancer. a literature-based modal analysis of costs in the Italian National Health Service. Clin. Ther. (2004) 26:1546-1561.
33. OKUBO I, KONDO M, TOI M et al.: Cost-effectiveness of letrozole versus tamoxifen as first-line hormonal therapy in treating postmenopausal women with advanced breast cancer in Japan. Gan. To. Kagaku Ryoho (2005) 32:351-363.
34. SONNENBERG F, BECK R: Markov models in medical decision making: a practical guide. Med. Decis. Making (1993) 13:322-338.
35. EARLY BREAST CANCER TRIALISTS' COLLABORATIVE GROUP: Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomized trials. Lancet (2005) 365:1687-1717.
36. WINER EP, HUDIS C, BURSTEIN HJ et al.: American society of clinical oncology technology assessment on the use of aromatase inhibitors for postmenopausal women with hormone receptor-positive breast cancer: status report 2004. J. Clin. Oncol. (2005) 23:619-629.
37. COOMBES RC et al.; ON BEHALF OF THE INTERGROUP EXEMESTANE STUDY (IES): Exemestane improves disease-free survival in postmenopausal patients with early breast cancer after two to three years of tamoxifen: a double blind randomized trial. N. Engl. J. Med. (2004) 350:1081-1092.
38. GLAZIOU PP, COLE BF, GELBER R et al.: Quality adjusted survival analysis with repeated quality of life measures. Stat. Med. (1998) 17:1215-1229.
39. NABHOLTZ JM, BUDZAR A, POLLACK M et al.: Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multi-center randomized trial. Arimidex Study Group. J. Clin. Oncol. (2000) 18:3758-3767.
40. BONNETERRE J, BUZDAR A, NABHOLTZ J-M et al.: Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor positive advanced breast carcinoma. Cancer (2001) 92:2247-2258.
41. MEMBERS OF THE BREAST CANCER DISEASE SITE GROUP: The role of aromatase inhibitors in the treatment of post-menopausal women with metastatic breast cancer. Toronto Ont: Cancer Care Ontario, Program in Evidence-Based Care (2003). (Practice Guideline Report 1-5).
42. BONNETERRE J, THURLIMANN B, ROBERTSON JF et al.: Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the tamoxifen or arimidex randomized group efficacy and tolerability study. J. Clin. Oncol. (2000) 18:3748-3757.
43. MILLA SANTOS A, MILLA L, RALLO L: Phase III trial of anastrozole vs tamoxifen in postmenopausal patients with hormone-dependent advanced breast cancer. Eur. J. Cancer (2001) 37(Suppl. 5):4.
44. SHIN I, MILLER T, ARTEAGA CL: ErbB receptor signaling and therapeutic resistance to aromatase inhibitors. Clin. Cancer Res. (2006) 12(3 Part 2):S1008-S1012.
45. OSBORNE CK, SHOU J, MASSARWEH S, SCHIFF R: Crosstalk between estrogen receptor and growth factor receptor pathways as a cause of endocrine therapy resistance in breast cancer. Clin. Cancer Res. (2005) 11(2 Part 2):S865-S870.